Understanding Glaucoma Caused by Myocilin Protein Issues
Characterization of purified myocilin: glaucoma as a protein misfolding disease
This research helps us understand how a specific protein called myocilin causes a type of glaucoma, aiming to find new ways to treat vision loss.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11075330 on NIH RePORTER |
What this research studies
Glaucoma is a serious eye condition that can lead to blindness, often due to high pressure inside the eye. This pressure happens when fluid doesn't drain properly from the eye, often because of problems in a tissue called the trabecular meshwork. For some people, especially younger patients, glaucoma is caused by changes in a protein called myocilin. This project looks closely at how myocilin protein misfolds and builds up, which damages eye cells and speeds up vision loss. By understanding these tiny details, we hope to develop new treatments that go beyond just lowering eye pressure.
Who could benefit from this research
Good fit: This foundational research is most relevant to patients with hereditary open-angle glaucoma caused by myocilin mutations, as it seeks to understand the specific disease mechanisms.
Not a fit: Patients whose glaucoma is not linked to myocilin mutations or protein misfolding may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to new medications that target the root cause of myocilin-related glaucoma, potentially preventing vision loss more effectively than current treatments.
How similar studies have performed: Previous studies from this research group have already provided key molecular insights into myocilin's role in glaucoma, laying the groundwork for new therapeutic approaches.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Lieberman, Raquel L — Georgia Institute of Technology
- Study coordinator: Lieberman, Raquel L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.